"Precise 3D printing with hydrogels, followed by perfusion of cells into the printed scaffold is the best way to achieve this, and we are thankful our work with United Therapeutics has given us the opportunity to advance and perfect this technology." CollPlant previously worked with 3D Systems to bioprint a number of tissue scaffolds (pictured). Photo via CollPlant. Increasing R&D efforts in regenerative medicine Having previously cited healthcare as an area of growth for 2020 and after experiencing significant progress in this area, 3D Systems is now flushing additional resources into its regenerative medicine R&D activities to widen the scope of potential applications and increase its expertise and technological know-how within this field. The firm previously announced a collaboration with Israeli bioprinting material developer CollPlant for the joint development of tissue and scaffold bioprinting processes for third party collaborators.